Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Advanced Breast Cancer × olaparib × Clear all

Phase

Status

Unknown 1 Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Ovarian Neoplasms 11 Neoplasms 7 Fallopian Tube Neoplasms 7 Pancreatic Neoplasms 6 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 5 Endometrial Neoplasms 4 Neuroendocrine Tumors 3 Carcinoma, Ovarian Epithelial 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Glioma 2 Glioblastoma 2 Cholangiocarcinoma 2 Advanced Solid Tumor 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 SCLC,Extensive Stage 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1

Interventions

Fulvestrant 3 trastuzumab deruxtecan 2 Vinorelbine 2 talazoparib 1 pyrotinib 1 olaparib 1 eribulin 1 elacestrant 1 disitamab vedotin 1 dalpiciclib 1 apatinib 1 Ritonavir 1 Radiotherapy 1 Itraconazole 1 Immunotherapy, Adoptive 1 Capecitabine 1 Aromatase Inhibitors 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05536128 2025-04-17

Post-CDK

Seoul National University Hospital

Phase 2 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡